Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

Ying Li1,2 *, Jia-Jing Lu1,2 *, Xiao-Yuan Zhong1,2 *, Ying-Yuan Yu1,2 *, Ning Yu,1,2 Yu Wang,1,2 Xue-Mei Yi,1,2 Yang-Feng Ding,1,2 Yu-Ling Shi1,2 1Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Repub...

Full description

Bibliographic Details
Main Authors: Li Y, Lu JJ, Zhong XY, Yu YY, Yu N, Wang Y, Yi XM, Ding YF, Shi YL
Format: Article
Language:English
Published: Dove Medical Press 2022-10-01
Series:Clinical, Cosmetic and Investigational Dermatology
Subjects:
biologics
drug survival
real-world
psoriasis
ixekizumab
secukinumab
guselkumab
adalimumab.
Online Access:https://www.dovepress.com/drug-survival-outcomes-associated-with-the-real-world-use-of-ixekizuma-peer-reviewed-fulltext-article-CCID

Internet

https://www.dovepress.com/drug-survival-outcomes-associated-with-the-real-world-use-of-ixekizuma-peer-reviewed-fulltext-article-CCID

Similar Items